At this moment the role of new protease inhibitors in the onset of HIV-related demyelinating polyneuropathy remains a controversial topic. We describe the improvement of AIDP after introduction of boosted Darunavir plus Tenofovir/ Emtricitabine in a HIV positive patient naïve for antiretroviral therapy. The regression of the neurological symptoms was associated with the introduction of protease inhibitors in absence of traditional treatment strategies for demyelinating polyneuropathy. Further studies are needed to establish their potential use in the treatment of HIV-1 related demyelinating polyneuropathy.
Keywords: Generic drug; Co-formulation; Antiretroviral therapy.
Articolo presente in – HAART and correlated pathologies n. 11 –
In patients coinfected with HIV the natural history of syphilis may be altered and the immune defect may account for differences in the host immune response to Treponema pallidum. Anyway many questions remain about interactions between HIV and syphilis during the HAART-related restoration of protective pathogen-specific immune responses. We describe the case of a HIV-positive patient with ocular syphilis who presented an unexpected immune response to coinfection.
Keywords: Ocular syphilis; HIV; Immune reconstitution; HAART.
Articolo presente in – HAART and correlated pathologies n. 7 –
Patients under combined antiretroviral therapy (cART) can experience unexplained episodes of transient HIV-RNA<1000 copies/ml preceded and followed by undetectable viraemia. The commonest hypothesis for blips is that are due to reduced adherence. It is not clear whether blips predict future virologic failure. Forty-five HIV-infected experienced patients with episodes of blips under optimal cART for at least 48 weeks were studied for level of adherence, CD4+, HIV-RNA, genotyping mutations and levels of adherence. All patients had been heavily pretreated. Good or optimal adherence was reported for all patients. The mean number of viral blips was 1.89. No statistical association was found between the number of blips and adherence scores. In this study patients with history of multiple blips presented a 28.8% risk of virologic failure despite good or optimal levels of adherence. Levels of adherence cannot always explain transient relapse of viraemia and other factors probably sustain blips. In addition, some patients with blips experienced a subsequent virologic failure despite good or optimal adherence. Changing therapy may be a prudent strategy for preserving future therapeutic options in experienced patients with blips. Keywords: Blips; Adherence; Resistance; Virologic failure; Multi-experienced patients.
Articolo presente in – HAART and correlated pathologies n. 2 –